Literature DB >> 1551528

Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort.

B J Reid1, P L Blount, C E Rubin, D S Levine, R C Haggitt, P S Rabinovitch.   

Abstract

To determine whether or not flow-cytometric evidence of aneuploidy and increased G2/tetraploid fractions predispose to neoplastic progression in Barrett's esophagus, 62 patients with Barrett's esophagus were evaluated prospectively for a mean interval of 34 months. Nine of 13 patients who showed aneuploid or increased G2/tetraploid populations in their initial flow-cytometric analysis developed high-grade dysplasia or adenocarcinoma during follow-up; none of the 49 patients without these abnormalities progressed to high-grade dysplasia or cancer (P less than 0.0001). Neoplastic progression was characterized by progressive flow-cytometric and histological abnormalities. Patients who progressed to high-grade dysplasia and carcinoma frequently developed multiple aneuploid populations of cells that were detectable flow-cytometrically. Similarly, patients appeared to progress through a phenotypic sequence that could be recognized histologically by the successive appearance of Barrett's metaplasia negative for dysplasia, abnormalities in the indefinite/low-grade dysplasia range, high-grade dysplasia, and eventually adenocarcinoma. These and prior results suggest that neoplastic progression in Barrett's esophagus occurs in a subset of patients who have an acquired genomic instability that generates abnormal clones of cells, some of which have aneuploid or increased G2/tetraploid DNA contents. With continued genomic instability, multiple aneuploid subclones may evolve, one of which may ultimately acquire the ability to invade and become an early carcinoma. The combination of histology and flow cytometry can be used to identify a subset of patients with Barrett's esophagus who merit more frequent endoscopic surveillance for the early detection of high-grade dysplasia or carcinoma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551528

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  83 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

Review 2.  Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.

Authors:  J A Jankowski; N A Wright; S J Meltzer; G Triadafilopoulos; K Geboes; A G Casson; D Kerr; L S Young
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

3.  Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR.

Authors:  T G Paulson; P C Galipeau; B J Reid
Journal:  Genome Res       Date:  1999-05       Impact factor: 9.043

4.  Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma.

Authors:  J W van Sandick; J J van Lanschot; B W Kuiken; G N Tytgat; G J Offerhaus; H Obertop
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

5.  Time gated fluorescence spectroscopy in Barrett's oesophagus.

Authors:  M-A E J Ortner; B Ebert; E Hein; K Zumbusch; D Nolte; U Sukowski; J Weber-Eibel; B Fleige; M Dietel; M Stolte; G Oberhuber; R Porschen; B Klump; H Hörtnagl; H Lochs; H Rinneberg
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 6.  Report of an Amsterdam working group on Barrett esophagus.

Authors:  G J A Offerhaus; P Correa; S van Eeden; K Geboes; P Drillenburg; M Vieth; M L van Velthuysen; H Watanabe; P Sipponen; F J W ten Kate; F T Bosman; A Bosma; A Ristimaki; H van Dekken; R Riddell; G N J Tytgat
Journal:  Virchows Arch       Date:  2003-09-27       Impact factor: 4.064

7.  Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.

Authors:  Rebecca E Rudolph; Thomas L Vaughan; Alan R Kristal; Patricia L Blount; Douglas S Levine; Patricia C Galipeau; Laura J Prevo; Carissa A Sanchez; Peter S Rabinovitch; Brian J Reid
Journal:  J Natl Cancer Inst       Date:  2003-05-21       Impact factor: 13.506

Review 8.  Surveillance in Barrett's oesophagus: a personal view.

Authors:  K K Basu; J S de Caestecker
Journal:  Postgrad Med J       Date:  2002-05       Impact factor: 2.401

9.  What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.

Authors:  N J Shaheen; J M Inadomi; B F Overholt; P Sharma
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

10.  Barrett's Esophagus: A Review of Biology and Therapeutic Approaches.

Authors:  Panteleimon Kountourakis; Jaffer A Ajani; Marta Davila; Jeffrey H Lee; Manoop S Bhutani; Julie G Izzo
Journal:  Gastrointest Cancer Res       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.